A DNA Plasmid Melanoma Cancer Vaccine, SCIB1, Combined with Nivolumab Plus Ipilimumab in Patients with Advanced Unresectable Melanoma: Efficacy and Safety Results from the Open-Label Phase 2 SCOPE Trial
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要